Support for Continued Surveillance of Nondysplastic Barrett Esophagus

In two studies, risk for progression to dysplasia did not decrease with successive negative endoscopies.

Studies estimating risk for histologic progression from nondysplastic Barrett esophagus (NDBE) that is persistently evident on sequential exams show mixed results. While some indicate a lower risk for progression, and therefore less need for regular surveillance in these patients, others conversely report increased risk over time.

In two retrospective cohort studies of patients with index exams showing NDBE, investigators assessed risk for histologic progression. In the first study, researchers at a single center followed 480 patients for an average of 3.8 years and found an overall annual rate of progression to dysplasia of 0.87% and to esophageal adenocarcinoma (EAC) of 0.11%. They found no association between the number of consecutive sur…

Reviewing Author

David A. Johnson, MD

Disclosures

Consultant/Advisory boardMedscape/WebMD; Pfizer; CRH Medical Corporation; Aries

EquityCRH Medical Corporation

Editorial boardsMedscape Gastroenterology

Leadership positions in professional societiesAmerican College of Gastroenterology Research Institute Board of Directors